Evelo Biosciences Investor Relations Material
Latest events
Q4 2022
Evelo Biosciences
Q3 2023
9 Nov, 2023
Q2 2023
14 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Evelo Biosciences Inc
Access all reports
Evelo Biosciences, Inc. (EVLO) is a clinical-stage biotechnology company engaged in the discovery and development of novel oral medicines. These medicines are designed to act on immune cells within the small intestine, with the aim of achieving systemic effects. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the OTC markets.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
EVLO
Country
🇺🇸 United States